Amy Elazzouzi was named Chief Financial Officer of Aura Biosciences, Inc. As of November 6, 2026, Aura Biosciences, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 4, 2026 to August 11, 2026, naming 4 appointments (Form 8-K, August 11, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Aura Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Amy Elazzouzi · Role: Senior Vice President, Finance · Effective: 2026-09-02 · 8-K, 2026-08-11
- · In / out: In · Person: Jeremy Bender · Role: Director · Effective: 2026-07-07 · 8-K, 2026-07-08
- · In / out: In · Person: Natalie Holles · Role: Chief Executive Officer · Effective: 2026-04-30 · 8-K, 2026-05-04
Aura Biosciences, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-04 to 2026-08-11. They name 3 people. Every row below is cited to the filing it comes from, and this page adds each new change as Aura Biosciences, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-08-11 (layoff filings and notices).
Also on the record for Aura Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.03% of the class | 5%+ stakes | Source |
| October 1, 2026 | Stake report, Schedule 13G, by ForGrowth III PA B.V. | 5.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by LONG FOCUS CAPITAL MANAGEMENT, LLC | 4.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 5.6% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 8.44% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.4% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by Chen Yu | 9.9% of the class | 5%+ stakes | Source |
| May 11, 2026 | Stake report, Schedule 13D/A, by Matrix Capital Management Company LP | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Rajesh Parekh, Ph.D. | 3.335% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 6.3% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Aura Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aura Biosciences, Inc. and the records around it.
Aura Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Layoff notices Aug 2026
- Who owns it
Companies that share a holder
- Matrix Capital Management Company LP also filed stake reports on 2 other companies: Zentalis Pharmaceuticals, Inc. (Jan 2026), Maze Therapeutics, Inc. (Nov 2025)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- LONG FOCUS CAPITAL MANAGEMENT, LLC also filed stake reports on 8 other companies: STANDARD BIOTOOLS INC. (Aug 2026), BICYCLE THERAPEUTICS PLC (May 2026), ONITY GROUP INC. (May 2026)
Watch Aura Biosciences, Inc.
Get an email when Aura Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aura Biosciences, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aura Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aura Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-11 | In | Senior Vice President, Finance | 2026-09-02 | 8-K, 2026-08-11 | |
| 2026-08-11 | In | Chief Financial Officer | 8-K, 2026-08-11 | ||
| 2026-07-08 | In | Director | 2026-07-07 | 8-K, 2026-07-08 | |
| 2026-05-04 | In | Chief Executive Officer | 2026-04-30 | 8-K, 2026-05-04 |
Who leads Aura Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Senior Vice President, Finance: Amy Elazzouzi, appointed, effective 2026-09-02 (filed 2026-08-11).
- Chief Financial Officer: Amy Elazzouzi, appointed (filed 2026-08-11).
- Director: Jeremy Bender, appointed, effective 2026-07-07 (filed 2026-07-08).
- Chief Executive Officer: Natalie Holles, appointed, effective 2026-04-30 (filed 2026-05-04).
New leaders reset buying decisions — get the Full Report on Aura Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Senior Vice President, Finance at Aura Biosciences, Inc., with the record behind each one.
Find candidates like Finance at Aura Biosciences, Inc.Every change, in the filing's words
Appointed: Amy Elazzouzi, Senior Vice President, Finance, effective 2026-09-02
Appointment of Interim Principal Financial Officer In connection with Mr. Gibney's departure, on August 6, 2026, the Board appointed Amy Elazzouzi as the Company's Senior Vice President, Finance, Treasurer and Secretary, effective as of September 2, 2026 (the "Elazzouzi Effective Date").
Appointed: Amy Elazzouzi, Chief Financial Officer
In addition, the Board confirmed that, effective as of the Elazzouzi Effective Date, Ms. Elazzouzi will serve as the Company's interim principal financial officer until such time as the Board appoints a Chief Financial Officer of the Company.
- Appointment of Chief Operating Officer On August 6, 2026, the Board appointed Susan Abu-Absi, Ph.D., age 52, as the Company's Chief Operating Officer, effective as of August 10, 2026 (the "Start Date").
- Prior to joining the Company, Dr. Abu-Absi served as Chief Operating Officer at Be Biopharma, Inc. from February 2025 to June 2026, where she led the company's operational strategy and execution.
- Prior to Be Biopharma, Dr. Abu-Absi was Chief Technology Officer at 2seventy bio, Inc. from November 2021 to May 2024, leading technical development, supply and quality.
- Previously, Dr. Abu-Absi was Senior Vice President, Technical Development & Operations at bluebird bio, Inc. from January 2019 to November 2021, and earlier in her career held senior leadership roles at Bristol Myers Squibb and Bayer Healthcare.
- Dr. Abu-Absi holds a Ph.D. in Chemical Engineering from the University of Minnesota and a B.S. in Chemical Engineering from the University of Toledo.
- In connection with her appointment as Chief Operating Officer, Dr. Abu-Absi entered into an offer letter (the "Abu-Absi Employment Offer Letter"), effective as of the Start Date, setting forth the terms of her employment with the Company.
- Pursuant to the Abu-Absi Employment Offer Letter, Dr. Abu-Absi will be paid an annual base salary of $520,000.
Appointed: Jeremy Bender, Director, effective 2026-07-07
On July 3, 2026, the Board of Directors (the "Board") of Aura Biosciences, Inc. (the "Company") increased the size of the Board from six to seven directors and unanimously appointed Jeremy Bender, Ph.D., M.B.A., as a Class II director, effective July 7, 2026 (the "Effective Date"), to fill the newly created vacancy.
- Dr. Bender's term will expire at the Company's 2029 annual meeting of stockholders.
- Dr. Bender also has been appointed to the Compensation Committee and the Nominating and Corporate Governance Committee of the Board, effective on the Effective Date.
- The Board has determined that Dr. Bender qualifies as an independent director and is qualified to serve under the applicable rules and regulations of the Securities and Exchange Commission (the "SEC") and the listing rules of the Nasdaq Stock Market LLC.
- For his service on the Board, Dr. Bender is eligible to receive the same cash compensation as the Company's other non-employee directors in accordance with the Company's Amended and Restated Non-Employee Director Compensation Policy, which was amended and restated by the Board on June 11, 2026 and is described below (the "Policy").
- Consistent with the Policy, Dr. Bender has received an initial, one-time stock option award to purchase 60,000 shares of the Company's common stock, $0.00001 par value per share ("Common Stock"), and an initial, one-time restricted stock unit award covering 30,000 shares of Common Stock.
- These initial awards will vest in equal annual installments over three years, and will generally stop vesting if Dr. Bender ceases to serve on the Board.
Appointed: Natalie Holles, Chief Executive Officer, effective 2026-04-30
On April 29, 2026, the Board of Directors (the "Board") of Aura Biosciences, Inc. (the "Company") appointed Natalie Holles as the Company's Chief Executive Officer and President and as a Class I director with a term expiring at the Company's 2028 annual meeting of stockholders, effective as of April 30, 2026 (the "Effective Date").
- Ms. Holles will succeed Dr. Elisabet de los Pinos, the Company's founder, who has notified the Company of her departure from her role at the Company as Chief Executive Officer and President and as a director of the Company, effective as of the Effective Date.
- Natalie Holles, age 53, is a seasoned industry executive with significant rare disease operational and commercialization experience.
- From August 2021 to December 2025, Ms. Holles served as Chief Executive Officer and a member of the board of directors of Third Harmonic Bio, Inc., a biopharmaceutical company that focused on dermal, respiratory and gastrointestinal inflammatory diseases.
- From January 2020 through March 2021, Ms. Holles served as President and Chief Executive Officer at Audentes Therapeutics, Inc., a biotechnology company focused on genetic medicines, and prior to that served as their President and Chief Operating Officer beginning in May 2018 and Senior Vice President, Chief Operating Officer beginning in August 2015.
- Previously, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc., a rare disease pharmaceutical company, from June 2013 through its acquisition by Horizon Pharma, plc in May 2015.
Tools for this story
Each opens in a new tab, filled in for Aura Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.